Our Progress
Latest Publications
The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma.
Bharathy N, Berlow NE, Wang E, Abraham J, Settelmeyer TP, Hooper JE, Svalina MN, Ishikawa Y, Zientek K, Bajwa Z, Goros MW, Hernandez BS, Wolff JE, Rudek MA, Xu L, Anders NM, Pal R, Harrold AP, Davies AM, Ashok A, Bushby D, Mancini M, Noakes C, Goodwin NC, Ordentlich P, Keck J, Hawkins DS, Rudzinski ER, Chatterjee B, Bächinger HP, Barr FG, Liddle J, Garcia BA, Mansoor A, Perkins TJ, Vakoc CR, Michalek JE, Keller C.
Shape analysis of the basioccipital bone in Pax7-deficient mice.
Cates J, Nevell L, Prajapati SI, Nelon LD, Chang JY, Randolph ME, Wood B, Keller C, Whitaker RT.
Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species.
Davis LE, Jeng S, Svalina MN, Huang E, Pittsenbarger J, Cantor EL, Berlow N, Seguin B, Mansoor A, McWeeney SK, Keller C.
Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma.
Bharathy N, Svalina MN, Settelmeyer TP, Cleary MM, Berlow NE, Airhart SD, Xiang S, Keck J, Hayden JB, Shern JF, Mansoor A, Lathara M, Srinivasa G, Langenau DM, Keller C.
NFκB signaling in alveolar rhabdomyosarcoma.
Cleary MM, Mansoor A, Settelmeyer T, Ijiri Y, Ladner KJ, Svalina MN, Rubin BP, Guttridge DC, Keller C.
EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.
Randolph ME, Cleary MM, Bajwa Z, Svalina MN, Young MC, Mansoor A, Kaur P, Bult CJ, Goros MW, Michalek JE, Xiang S, Keck J, Krasnoperov V, Gill P, Keller C.
The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma.
Ignatius MS, Hayes MN, Lobbardi R, Chen EY, McCarthy KM, Sreenivas P, Motala Z, Durbin AD, Molodtsov A, Reeder S, Jin A, Sindiri S, Beleyea BC, Bhere D, Alexander MS, Shah K, Keller C, Linardic CM, Nielsen PG, Malkin D, Khan J, Langenau DM.
Loss of Ptpn11 (Shp2) drives satellite cells into quiescence.
Griger J, Schneider R, Lahmann I, Schöwel V, Keller C, Spuler S, Nazare M, Birchmeier C.
Combination therapy design for maximizing sensitivity and minimizing toxicity.
Matlock K, Berlow N, Keller C, Pal R.
Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification.
Dey D, Bagarova J, Hatsell SJ, Armstrong KA, Huang L, Ermann J, Vonner AJ, Shen Y, Mohedas AH, Lee A, Eekhoff EM, van Schie A, Demay MB, Keller C, Wagers AJ, Economides AN, Yu PB.
Our mission is to translate scientific discovery into clinical trials by understanding and proving new disease-specific treatment options for children with cancer.
This concept was emphasized in the Institute of Medicine Report, Making Better Drugs for Children with Cancer in 2005. cc-TDI now fills this crucially needed role created as a result of the ever-changing climate of federal funding for childhood cancer research.
